In a multicenter randomized trial of 441 patients with transthyretin amyloid CMP (either variant or wild-type ATTR amyloidosis, of which 76% were wild-type), tafamidis, which binds to transthyretin and prevents tetramer dissociation and amyloidogenesis, was associated with lower all-cause mortality than the placebo (78 of 264 [29.5%] vs. 76 of 177 [42.9%]; HR: 0.70; 95% CI 0.51 to 0.96), as well as a lower rate of CV-related hospitalizations, with a relative risk ratio of 0.68 (0.48 per year vs. 0.70 per year; 95% CI 0.56 to 0.81). This evidence concerns the gene TTR and amyloidosis.